Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Subscribe To Our Newsletter & Stay Updated
